Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-582-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Sensitisation data (human)
Administrative data
- Endpoint:
- sensitisation data (humans)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Between 25 April 1994 and 29 April 1994
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study conducted in accordance with generally accepted scientific principles, possibly with incomplete reporting or methodological deficiencies, which do not affect the quality of the relevant results.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 994
- Report date:
- 1994
Materials and methods
- Type of sensitisation studied:
- skin
- Study type:
- study with volunteers
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: no guideline stated
- Deviations:
- no
- Principles of method if other than guideline:
- To determine and compare the relative primary irritation potential and estimate tolerability for subsequent occlusive RIFT studies of two (2) calcium sulfonate test articles when applied to the skin of human subjects for 48-hours under occlusive patches.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Reference substance 002
- Cas Number:
- 61789-86-4
- Details on test material:
- Description: Brown viscous liquid
Constituent 1
Method
- Type of population:
- general
- Ethical approval:
- confirmed and informed consent free of coercion received
- Subjects:
- Twenty-seven (27) subjects, 4 males and 23 females, ranging in age from 19 to 61 years, were empaneled to test 1%, 3%, 10% and 30% concentrations of the calcium sulfonate test articles.
The subjects were informed of the nature of the test, including possible adverse reactions. Written informed consent was obtained.
Additionally, the subjects were considered dependable and able to read and understand instructions.
The subjects did not exhibit any physical or dermatological conditions which would have precluded application of the calcium sulfonate test articles. - Clinical history:
- The subjects did not exhibit any physical or dermatological condition that would have precluded application of the calcium sulfonate test article.
- Route of administration:
- dermal
- Details on study design:
- The 48-Hour Patch Test was conducted as follows:
The study was initiated on April 25, 1994 and observations (skin reactivity) were made on April 27, 1994 (48-hours) and April 29, 1994 (96-hours).
Approximately 0.2 mL of each calcium sulfonate test article was placed onto Parke-Davis Readi-Bandage occlusive patches. The patch test units were applied to the back of each subject for a period of 48-hours.
At the end of the 48-hour contact period, the patch test units were removed at the Clinic and scored for dermal reactivity. A second reading was taken 48-hours later (96-hours post-application).
Results and discussion
- Results of examinations:
- Test Articles: Calcium sulfonates
Twenty-seven (27) subjects satisfactorily completed Panel No. 94042. There were no discontinued subjects.
The calcium sulfonate test Article Calcium sulfonate (Total Base Number = 100) exhibited negligible dermal irritancy at all four test concentrations, following 48 hours of occlusive patch testing.
The calcium sulfonate test Article Calcium sulfonates (Total Base Number = 82) exhibited negligible dermal irritancy at 1 % and 3%, very mild irritation at 10% and marked to severe irritation at the 30% concentration, following 48 hours of occlusive patch testing.
For the purpose of repeated insult (occlusive) patch testing (RIPT), test concentrations of 30% for Calcium sulfonate (TBN = 100) and 3% for Calcium sulfonate (TBN = 82) are estimated to be tolerable for a human test population.
For the purpose of repeated insult (semi-occlusive) patch testing, test concentrations of 10% for either calcium sulfonate test article are estimated to be tolerable for a human test population.
Any other information on results incl. tables
The following summarizes the Mean Irritation Scores observed for each of the calcium sulfonate test articles at the various concentrations tested:
Test Article Calcium sulfonate (TBN = 100)
48-hours
1% 3% 10% 30%
0.02 0.02 0.02 0.04
96 -hours
1% 3% 10% 30%
0.00 0.00 0.00 0.00
Test Article Calcium sulfonate (TBN = 82)
48-hours
1% 3% 10% 30%
0.02 0.02 0.13 1.26
96 -hours
1% 3% 10% 30%
0.00 0.00 0.04 0.59
TABLE 1 | |||||||||
Individual Test Subject Irritation Scores | |||||||||
Test Article: Calcium sulfonate (TBN = 82) |
|||||||||
Subject No. |
48-Hours |
96-Hours |
|||||||
Test Concentration |
|||||||||
1% |
3% |
10% |
30% |
1% |
3% |
10% |
30% |
||
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
6 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
7 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
8 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
9 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
11 |
0 |
0 |
0 |
+ |
0 |
0 |
0 |
0 |
|
12 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
13 |
+ |
+ |
+ |
+ |
0 |
0 |
0 |
0 |
|
14 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
15 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
16 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
17 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
18 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
19 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
20 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
21 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
22 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
23 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
24 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
25 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
26 |
0 |
0 |
0 |
0 |
0 |
0 |
0 | 0 | |
27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Scale: | 0 = | No evidence of any effect | |||||||
+ = | Barely Perceptible (Minimal, faint, uniform or spotty erythema) | ||||||||
1 = | Mild (pink, uniform erythema covering most of the contact site) | ||||||||
2 = | Moderate (Pink-red erythema uniform in the entire contact site) | ||||||||
3= | Marked (Bright-red erythema with/without petechiae or papules) | ||||||||
4= | Severe (Deep-red erythema with/without vesiculation or weeping) |
TABLE 2 | |||||||||
Individual Test Subject Irritation Scores | |||||||||
Test Article: Calcium sulfonate (TBN = 100) |
|||||||||
Subject No. |
48-Hours |
96-Hours |
|||||||
Test Concentration |
|||||||||
1% |
3% |
10% |
30% |
1% |
3% |
10% |
30% |
||
1 |
0 |
0 |
+ |
2 |
0 |
0 |
0 |
1d |
|
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3 |
0 |
0 |
0 |
+ |
0 |
0 |
0 |
0 |
|
4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
5 |
0 |
0 |
+ |
2 |
0 |
0 |
0 |
+d |
|
6 |
0 |
0 |
0 |
2e |
0 |
0 |
0 |
+d |
|
7 |
0 |
0 |
1 |
3ev |
0 |
0 |
+ |
1d |
|
8 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
+d |
|
9 |
0 |
0 |
0 |
+ |
0 |
0 |
0 |
+ |
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
11 |
0 |
0 |
0 |
2e |
0 |
0 |
0 |
1 |
|
12 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
1d |
|
13 |
+ |
+ |
+ |
4vw |
0 |
0 |
0 |
3d |
|
14 |
0 |
0 |
0 |
+p |
0 |
0 |
0 |
+ |
|
15 |
0 |
0 |
0 |
+ |
0 |
0 |
0 |
+ |
|
16 |
0 |
0 |
+ |
1 |
0 |
0 |
0 |
0 |
|
17 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0d |
|
18 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
|
19 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
20 |
0 |
0 |
+ |
2 |
0 |
0 |
0 |
1d |
|
21 |
0 |
0 |
0 |
+ |
0 |
0 |
0 |
0 |
|
22 |
0 |
0 |
0 |
+ |
0 |
0 |
+* |
1** |
|
23 |
0 |
0 |
0 |
+ |
0 |
0 |
0 |
1pd |
|
24 |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
1d |
|
25 |
0 |
0 |
0 |
1e |
0 |
0 |
0 |
+ |
|
26 |
0 |
0 |
0 |
1e |
0 |
0 |
0 |
0 |
|
27 |
0 |
0 |
0 |
+ |
0 |
0 |
0 |
+ |
|
Scale: |
0 = |
No evidence of any effect |
|||||||
+ = |
Barely Perceptible (Minimal, faint, uniform or spotty erythema) |
||||||||
1 = |
Mild (pink, uniform erythema covering most of the contact site) |
||||||||
2 = |
Moderate (Pink-red erythema uniform in the entire contact site) |
||||||||
3 = |
Marked (Bright-red erythema with/without petechiae or papules) |
||||||||
4 = |
Severe (Deep-red erythema with/without vesiculation or weeping) |
||||||||
e = |
Mild to moderate oedema |
||||||||
p = |
mild papular reaction |
||||||||
w = |
weeping |
||||||||
d = |
mild to moderate dryness |
||||||||
* = |
(168 hr = 0) |
||||||||
v = |
moderate vesiculation |
||||||||
** = |
(168 hr = +d) |
Applicant's summary and conclusion
- Conclusions:
- The calcium sulfonate test Article Calcium sulfonate (Total Base Number = 100) exhibited negligible dermal irritancy at all four test concentrations, following 48 hours of occlusive patch testing.
The calcium sulfonate test Article Calcium sulfonate (Total Base Number = 82) exhibited negligible dermal irritancy at 1 % and 3%, very mild irritation at 10% and marked to severe irritation at the 30% concentration, following 48 hours of occlusive patch testing.
For the purpose of repeated insult (occlusive) patch testing (RIPT), test concentrations of 30% for Calcium sulfonate (TBN = 100= and 3% for Calcium sulfonate (TBN = 82) are estimated to be tolerable for a human test population.
For the purpose of repeated insult (semi-occlusive) patch testing, test concentrations of 10% for either calcium sulfonate test article are estimated to be tolerable for a human test population. - Executive summary:
To determine and compare the relative primary irritation potential and estimate tolerability for subsequent occlusive RIFT studies of two (2) calcium sulfonate test articles when applied to the skin of human subjects for 48-hours under occlusive patches.
Twenty-seven (27) subjects, 4 males and 23 females, ranging in age from 19 to 61 years, were empaneled to test 1%, 3%, 10% and 30% concentrations of the calcium sulfonate test articles. The 48-Hour Patch Test was conducted.
Test Article Calcium sulfonate (Total Base Number = 100) exhibited negligible dermal irritancy at all four test concentrations, following 48 hours of occlusive patch testing.
Test Article Calcium sulfonate (Total Base Number = 82) exhibited negligible dermal irritancy at 1 % and 3%, very mild irritation at 10% and marked to severe irritation at the 30% concentration, following 48 hours of occlusive patch testing.
For the purpose of repeated insult (occlusive) patch testing (RIPT), test concentrations of 30% for Calcium sulfonate (TBN = 100) and 3% for Calcium sulfonate (TBN = 82) are estimated to be tolerable for a human test population.
For the purpose of repeated insult (semi-occlusive) patch testing, test concentrations of 10% for either calcium sulfonate test article are estimated to be tolerable for a human test population.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.